In brief: Prima, SciGen, Sonic
Thursday, 30 June, 2005
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
SciGen (ASX:SIE) managing director and CEO Mark Compton will leave the company on August 5. While he will remain as CEO till then, he has resigned as a director, effective June 29. SciGen is searching for a new CEO who is likely to be based in Asia.
Former CEO and executive director of the Melbourne Pathology Group, Lou Panaccio has joined the board of Sonic Healthcare (ASX:SHL) as a non-executive director. He will also replace Colin Jackson as a member of the Audit Committee.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
